Difference in recurrence frequencies of non-muscle-invasive-bladder tumors depending on optimal usage of intravesical immunotherapy of bacillus Calmette-Guérin
Background/Aim. The therapy with intravesical instillation of bacillus Calmette-Guérin (BCG) after transurethral resection (TUR) of the tumor is the gold standard of treatment of non-muscle invasive bladder cancer (NMIBC). The aim of this study was to compare the frequencies of reccurence b...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade
2015-01-01
|
| Series: | Vojnosanitetski Pregled |
| Subjects: | |
| Online Access: | http://www.doiserbia.nb.rs/img/doi/0042-8450/2015/0042-84501400072M.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849736540560818176 |
|---|---|
| author | Milošević Radovan Milović Novak Aleksić Predrag Lazić Miodrag Cerović Snežana Bančević Vladimir Košević Branko Marić Predrag Spasić Aleksandar Simić Dejan Kovačević Božidar |
| author_facet | Milošević Radovan Milović Novak Aleksić Predrag Lazić Miodrag Cerović Snežana Bančević Vladimir Košević Branko Marić Predrag Spasić Aleksandar Simić Dejan Kovačević Božidar |
| author_sort | Milošević Radovan |
| collection | DOAJ |
| description | Background/Aim. The therapy with intravesical instillation of bacillus
Calmette-Guérin (BCG) after transurethral resection (TUR) of the tumor is the
gold standard of treatment of non-muscle invasive bladder cancer (NMIBC). The
aim of this study was to compare the frequencies of reccurence between a
group of patients submitted to TUR + BCG therapy (group I) and a group of
patients submitted only to TUR (group II). Methods. The patients with NMIBC,
a total of 899, treated in our Institution from January 1, 2007 to March,
2013, were included in this study and divided into two groups: group I and
group II. These two groups were divided into three subgroups: solitary first
diagnosed tumor ≤ 3 cm (SFDGT), solitary first diagnosed tumor > 3 cm and
multiple first diagnosed tumors (MFDGT), and recedive tumors (RCT).
Statistical analysis was performed by using χ2-test and Kolmogorov-Smirnov
test. Results: In the group I a total of 133 cases had reccurence contrary to
75 in the group II, making a statistically highly significant difference.
Analysis of recurrences through the subgroups revealed: in the group I SFDGT
recurrence occured in 27 of the cases vs 9 cases in the group II; in the
group I MFDGT recurrence occured in 49 of the cases vs 31 in the group II (p
< 0.001), and finally, in the group I RCT recurrence occured in 57 cases vs
35 cases in the group II (p < 0.001). Conclusion. The obtained results
indicate no difference in the frequency of reccurence between the group I and
group II regarding SFDGT, but a very high significant difference regarding
those with MFDGT and RCT. These results should be taken into consideration in
everyday clinical practise. |
| format | Article |
| id | doaj-art-861ad6db4df94a0e97f2dbe9adc29ceb |
| institution | DOAJ |
| issn | 0042-8450 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade |
| record_format | Article |
| series | Vojnosanitetski Pregled |
| spelling | doaj-art-861ad6db4df94a0e97f2dbe9adc29ceb2025-08-20T03:07:14ZengMinistry of Defence of the Republic of Serbia, University of Defence, BelgradeVojnosanitetski Pregled0042-84502015-01-0172324124610.2298/VSP131030072M0042-84501400072MDifference in recurrence frequencies of non-muscle-invasive-bladder tumors depending on optimal usage of intravesical immunotherapy of bacillus Calmette-GuérinMilošević Radovan0Milović Novak1Aleksić Predrag2Lazić Miodrag3Cerović Snežana4Bančević Vladimir5Košević Branko6Marić Predrag7Spasić Aleksandar8Simić Dejan9Kovačević Božidar10University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade + Military Medical Academy, Clinic of Urology, BelgradeUniversity of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade + Military Medical Academy, Clinic of Urology, BelgradeUniversity of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade + Military Medical Academy, Clinic of Urology, BelgradeHospital Dr Dragiša Mišović, Department of Urology, BelgradeUniversity of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade + Military Medical Academy, Institute for Pathology, BelgradeUniversity of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade + Military Medical Academy, Clinic of Urology, BelgradeMilitary Medical Academy, Clinic of Urology, BelgradeMilitary Medical Academy, Clinic of Urology, BelgradeMilitary Medical Academy, Clinic of Urology, BelgradeMilitary Medical Academy, Clinic of Urology, BelgradeMilitary Medical Academy, Institute for Pathology, BelgradeBackground/Aim. The therapy with intravesical instillation of bacillus Calmette-Guérin (BCG) after transurethral resection (TUR) of the tumor is the gold standard of treatment of non-muscle invasive bladder cancer (NMIBC). The aim of this study was to compare the frequencies of reccurence between a group of patients submitted to TUR + BCG therapy (group I) and a group of patients submitted only to TUR (group II). Methods. The patients with NMIBC, a total of 899, treated in our Institution from January 1, 2007 to March, 2013, were included in this study and divided into two groups: group I and group II. These two groups were divided into three subgroups: solitary first diagnosed tumor ≤ 3 cm (SFDGT), solitary first diagnosed tumor > 3 cm and multiple first diagnosed tumors (MFDGT), and recedive tumors (RCT). Statistical analysis was performed by using χ2-test and Kolmogorov-Smirnov test. Results: In the group I a total of 133 cases had reccurence contrary to 75 in the group II, making a statistically highly significant difference. Analysis of recurrences through the subgroups revealed: in the group I SFDGT recurrence occured in 27 of the cases vs 9 cases in the group II; in the group I MFDGT recurrence occured in 49 of the cases vs 31 in the group II (p < 0.001), and finally, in the group I RCT recurrence occured in 57 cases vs 35 cases in the group II (p < 0.001). Conclusion. The obtained results indicate no difference in the frequency of reccurence between the group I and group II regarding SFDGT, but a very high significant difference regarding those with MFDGT and RCT. These results should be taken into consideration in everyday clinical practise.http://www.doiserbia.nb.rs/img/doi/0042-8450/2015/0042-84501400072M.pdfurinary bladder, neoplasmscarcinoma in situimmunotherapymycobacterium bovisrecurrence |
| spellingShingle | Milošević Radovan Milović Novak Aleksić Predrag Lazić Miodrag Cerović Snežana Bančević Vladimir Košević Branko Marić Predrag Spasić Aleksandar Simić Dejan Kovačević Božidar Difference in recurrence frequencies of non-muscle-invasive-bladder tumors depending on optimal usage of intravesical immunotherapy of bacillus Calmette-Guérin Vojnosanitetski Pregled urinary bladder, neoplasms carcinoma in situ immunotherapy mycobacterium bovis recurrence |
| title | Difference in recurrence frequencies of non-muscle-invasive-bladder tumors depending on optimal usage of intravesical immunotherapy of bacillus Calmette-Guérin |
| title_full | Difference in recurrence frequencies of non-muscle-invasive-bladder tumors depending on optimal usage of intravesical immunotherapy of bacillus Calmette-Guérin |
| title_fullStr | Difference in recurrence frequencies of non-muscle-invasive-bladder tumors depending on optimal usage of intravesical immunotherapy of bacillus Calmette-Guérin |
| title_full_unstemmed | Difference in recurrence frequencies of non-muscle-invasive-bladder tumors depending on optimal usage of intravesical immunotherapy of bacillus Calmette-Guérin |
| title_short | Difference in recurrence frequencies of non-muscle-invasive-bladder tumors depending on optimal usage of intravesical immunotherapy of bacillus Calmette-Guérin |
| title_sort | difference in recurrence frequencies of non muscle invasive bladder tumors depending on optimal usage of intravesical immunotherapy of bacillus calmette guerin |
| topic | urinary bladder, neoplasms carcinoma in situ immunotherapy mycobacterium bovis recurrence |
| url | http://www.doiserbia.nb.rs/img/doi/0042-8450/2015/0042-84501400072M.pdf |
| work_keys_str_mv | AT milosevicradovan differenceinrecurrencefrequenciesofnonmuscleinvasivebladdertumorsdependingonoptimalusageofintravesicalimmunotherapyofbacilluscalmetteguerin AT milovicnovak differenceinrecurrencefrequenciesofnonmuscleinvasivebladdertumorsdependingonoptimalusageofintravesicalimmunotherapyofbacilluscalmetteguerin AT aleksicpredrag differenceinrecurrencefrequenciesofnonmuscleinvasivebladdertumorsdependingonoptimalusageofintravesicalimmunotherapyofbacilluscalmetteguerin AT lazicmiodrag differenceinrecurrencefrequenciesofnonmuscleinvasivebladdertumorsdependingonoptimalusageofintravesicalimmunotherapyofbacilluscalmetteguerin AT cerovicsnezana differenceinrecurrencefrequenciesofnonmuscleinvasivebladdertumorsdependingonoptimalusageofintravesicalimmunotherapyofbacilluscalmetteguerin AT bancevicvladimir differenceinrecurrencefrequenciesofnonmuscleinvasivebladdertumorsdependingonoptimalusageofintravesicalimmunotherapyofbacilluscalmetteguerin AT kosevicbranko differenceinrecurrencefrequenciesofnonmuscleinvasivebladdertumorsdependingonoptimalusageofintravesicalimmunotherapyofbacilluscalmetteguerin AT maricpredrag differenceinrecurrencefrequenciesofnonmuscleinvasivebladdertumorsdependingonoptimalusageofintravesicalimmunotherapyofbacilluscalmetteguerin AT spasicaleksandar differenceinrecurrencefrequenciesofnonmuscleinvasivebladdertumorsdependingonoptimalusageofintravesicalimmunotherapyofbacilluscalmetteguerin AT simicdejan differenceinrecurrencefrequenciesofnonmuscleinvasivebladdertumorsdependingonoptimalusageofintravesicalimmunotherapyofbacilluscalmetteguerin AT kovacevicbozidar differenceinrecurrencefrequenciesofnonmuscleinvasivebladdertumorsdependingonoptimalusageofintravesicalimmunotherapyofbacilluscalmetteguerin |